Analysis of STEP clinical trials shows semaglutide more than halves risk of T2DMThe risk of type 2 diabetes mellitus (T2DM) is more than halved by weekly injections of new obesity drug semaglutide, according to...
STEP outcomes: Semaglutide could be ‘gamechanger’ in battle against obesityOne third (35%) of patients who received semaglutide for treating obesity lost more than one-fifth (greater than or equal to 20%) of...
Post-bariatric surgery exercise modulates brain regions associated with regulation of food intake4 days ago
Waist-to-height ratio is a better indicator of outcomes in patients with heart failure than BMI5 days ago